Christopher R. Aker
2021
In 2021, Christopher R. Aker earned a total compensation of $795.4K as SVP & General Counsel at Regulus Therapeutics, a 2% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $153,000 |
|---|---|
| Option Awards | $286,200 |
| Salary | $340,000 |
| Other | $16,224 |
| Total | $795,424 |
Aker received $340K in salary, accounting for 43% of the total pay in 2021.
Aker also received $153K in non-equity incentive plan, $286.2K in option awards and $16.2K in other compensation.
Rankings
In 2021, Christopher R. Aker's compensation ranked 9,496th out of 12,415 executives tracked by ExecPay. In other words, Aker earned more than 23.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,496 out of 12,415 | 24th |
Division Manufacturing | 4,211 out of 5,508 | 24th |
Major group Chemicals And Allied Products | 1,866 out of 2,378 | 22nd |
Industry group Drugs | 1,655 out of 2,099 | 21st |
Industry Pharmaceutical Preparations | 1,231 out of 1,549 | 21st |
Source: SEC filing on April 27, 2022.
Aker's colleagues
We found two more compensation records of executives who worked with Christopher R. Aker at Regulus Therapeutics in 2021.